Discussion Forums > Working Towards a Cure
Bluebird Bio Releases Data on Current Gene Therapy Trials
Sharmin:
I am hopeful that the news will be good. I am also worried about Sloan Kettering. I had really been hoping that their myelosuppression method would be more successful.
I wonder if the greater success bluebird is enjoying is due to the myeloablation or if they are using a superior method of gene transfer?
JV:
Andy, could you elaborate on Sloan a little more because I feel the same way. Delays, not much news, poor results, etc...
Canadian_Family:
You are right on Andy. Yes, when a stock reaches 42-43, insiders seems to be dumping the stock. Now the question is if external analyst have a target price of stock at 50-57, why would one just dump the stock at 42-43. Please see few examples, there are number of other examples.
CEO Nick Leschly sold 25,000 shares of bluebird bio stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $41.68, for a total transaction of $1,042,000.00
bluebird bio (NASDAQ:BLUE) Insider Mitchell H. Finer sold 18,000 shares of bluebird bio stock on the open market in a transaction dated Monday, December 1st. The stock was sold at an average price of $39.70, for a total value of $714,600.00....
Lets see what happens at ASH presentation.
Andy Battaglia:
The timing is interesting, but I don't want to read anything into it until we hear what is released at ASH.
JV, all I know is what Pat G said and it sounded like they are not currently beginning new patients in trials. My concern is the money side and what may be attempts to stifle the competition. I have very little faith in the top management at SK. I think they can be bought.
JV:
Thanks Andy, ya I agree with you. I wonder how much of Cooleys Funding goes into that research...
Navigation
[0] Message Index
[#] Next page
[*] Previous page
Go to full version